Compare KBDC & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KBDC | CMPX |
|---|---|---|
| Founded | 2021 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.7M | 927.5M |
| IPO Year | 2018 | 2020 |
| Metric | KBDC | CMPX |
|---|---|---|
| Price | $14.55 | $2.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $15.50 | $14.57 |
| AVG Volume (30 Days) | 230.7K | ★ 12.1M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | ★ 13.16% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $193.84 | N/A |
| Revenue Next Year | $9.00 | $934.41 |
| P/E Ratio | $34.10 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.06 | $1.61 |
| 52 Week High | $16.28 | $6.88 |
| Indicator | KBDC | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 48.26 | 34.36 |
| Support Level | $14.02 | $1.61 |
| Resistance Level | $15.02 | $3.54 |
| Average True Range (ATR) | 0.38 | 0.14 |
| MACD | -0.07 | 0.13 |
| Stochastic Oscillator | 7.41 | 78.75 |
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company, investing mainly in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation mainly through debt investments in middle-market companies.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.